SVA News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

SV

Mkt Cap

N/A

Volume

N/A

Next Earnings

November 6th

Chart Financials Earnings News About Dividends Insider Filings

Global Influenza Vaccine Market Report, 2026 Edition - Profiles GlaxoSmithKline, Pfizer, Sanofi, Moderna, and 9 Other PlayersThe global influenza vaccine market was valued at US$8.96 billion in 2024 and is projected to reach US$13.32 billion by 2030, growing at a 7% CAGR. Market expansion is driven by rising public health awareness, an aging population, government immunization programs, and increased R&D investment. Quadrivalent and inactivated vaccines lead the market, while cell-based technologies and pediatric segments show fastest growth. Key players include GlaxoSmithKline, Pfizer, Sanofi, Moderna, and others.GlobeNewswire Inc. · Aug 7, 2026

SINOVAC Management Statement Regarding Auditor ResignationSinovac Biotech Ltd. (NASDAQ: SVA) is facing a crisis as its external auditor has resigned, leading to a delay in filing its annual report with the SEC. The company's current board is reviewing actions taken by the former board, causing uncertainty and disruption to the company's operations and governance.GlobeNewswire Inc. · Apr 22, 2025

Respiratory Disease Vaccines Market Research Report 2025: Analysis and Forecast (2020-2030) Featuring GSK, Johnson & Johnson Services, Pfizer, Sanofi, Serum Institute of India, SINOVAC Biotech & MoreThe global respiratory disease vaccine market is expected to grow from $94.6 billion in 2024 to $101.56 billion by 2030, driven by factors such as the increasing prevalence of respiratory diseases, the aging population, and government vaccine mandates and recommendations.GlobeNewswire Inc. · Feb 6, 2025

$12.5 Bn Influenza Vaccine Market to 2032 by Vaccine Type, Technology, Age Group, Route of Administration, and RegionThe global influenza vaccine market is expected to grow from $6.7 billion in 2023 to $12.5 billion by 2032, driven by rising influenza cases, government initiatives, and the development of more effective vaccines.GlobeNewswire Inc. · Sep 9, 2024

Sernova Receives Orphan Drug and Rare Pediatric Disease Designations for its Hemophilia A Program from FDASernova announces research collaboration with Professor Antonia Follenzi, expert in Hemophilia A at the University of Piemonte Orientale Sernova announces research collaboration with Professor Antonia Follenzi, expert in Hemophilia A at the University of Piemonte OrientaleGlobeNewswire Inc. · Nov 27, 2023

Sernova Announces Positive Ongoing Interim Phase 1/2 Clinical Data for the Cell Pouch System™ for Type 1 Diabetes Trial at the 2023 IPITA, IXA, and CTRMS Joint CongressLONDON, Ontario and WINDHAM COUNTY, Conn., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today presented interim positive results from its ongoing Phase 1/2 clinical trial investigating islet allotransplantation into pre-vascularized Sernova Cell Pouch™ during an oral presentation at the 2023 IPITA, IXA, and CTRMS Joint Congress in San Diego, California. Enrollment in Cohort A, which utilizes the 8-channel Cell Pouch, is complete with post-transplant data available for periods of follow-up ranging from 6 months to 3.5 years. Enrollment in Cohort B, which utilizes the higher capacity Cell Pouch and a revised and better-tolerated immunosuppressive regimen, began in November 2022 and 6 of the 7 planned patients have now been successfully implanted.GlobeNewswire Inc. · Oct 27, 2023

Sernova to Provide Two Program Updates in Podium Presentations at 2023 IPITA CongressDr. Piotr Witkowski presenting new data from ongoing Phase 1/2 clinical trial of the Cell Pouch System™ in patients with type 1 diabetes (T1D)GlobeNewswire Inc. · Oct 11, 2023

Sernova Presents Compelling New Data on the Cell Pouch System™ as a Promising Treatment for Post-Operative Hypothyroidism at the 2023 American Thyroid Association Annual MeetingProof-of-concept data supports the clinical evaluation of the Cell Pouch System as a potential treatment for post-operative hypothyroidism Proof-of-concept data supports the clinical evaluation of the Cell Pouch System as a potential treatment for post-operative hypothyroidismGlobeNewswire Inc. · Sep 29, 2023

Sernova Investor Conference Call Previously Scheduled for September 15 Now Rescheduled for September 22LONDON, Ontario and WINDHAM COUNTY, Conn., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it has rescheduled the investor and analyst conference call previously scheduled for September 15 at 10 a.m. Eastern Time. The call will now occur on September 22 at 10 a.m. Eastern Time. The business strategy and update call remains as scheduled for October 5, 2023.GlobeNewswire Inc. · Sep 14, 2023

Sernova to Host Investor Calls to Introduce Newly Appointed CEO and Provide Business Update- Introduction of New CEO Cynthia Pussinen and Recently Appointed Chief Business Officer, Dr. Modestus Obochi, on September 15, 2023 -GlobeNewswire Inc. · Sep 13, 2023

SV

SVASinovac Biotech, Ltd

SVA

Pay with—

Available Balance0.00

Your PositionYou don't own any SVA yet.

Related Tickers

Earnings

Dividends

Last · Jul 8

Amount$55.00